Cite
MLA Citation
Kevin J Harrington et al.. “Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.” Lancet oncology, vol. 18, no. 8, n.d., pp. 1104–1115. http://access.bl.uk/ark:/81055/vdc_100049766196.0x000001